VRTX241206P320000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $506
Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
In 2025, US Biotech stocks are expected to rise significantly. jpmorgan's top pick is vertex pharmaceuticals (VRTX.US).
Vertex pharmaceuticals (Vertex) ranked first on the list of US biotechnology stock selections for 2025 released by jpmorgan.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals (NASDAQ:VRTX) Pulls Back 6.9% This Week, but Still Delivers Shareholders Strong 34% CAGR Over 3 Years
Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock
Vertex Trust Sells $3.79 Million in Shares
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals: Promising Growth With Suzetrigine Potential and Strategic Diversification
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $490
Vertex Pharmaceuticals (VRTX) Receives a Hold From Stifel Nicolaus
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Top 10 Most Expensive Stocks (Only 1 Gets a Quant Sell)